[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unresectable-pancreatic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unresectable-pancreatic-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,68,99,126,153,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100518161","alpha-radiation-emitters-for-the-treatment-of-pancreatic-cancer-for-the-treatment-of-locally-advanced-pancreatic-cancer-100518161",false,"NCT06026943","Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer","A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Histologically and\u002For cytologically proven NCCN locally advanced PC\n* Patients must have i) received at least one line of chemotherapy (any kind) OR ii) are medically unfit for further chemotherapy, AND iii) the tumor is still not deemed as resectable with radical surgery, or the patient does not wish to go through surgery.\n* DaRT indication validated by a multidisciplinary team.\n* Measurable lesion per RECIST (version 1.1) criteria\n* TC at Verona's center (not been over a month)\n* Lesion size ≤ 5 cm in the longest diameter\n* Age ≥18 years old\n* ECOG Performance Status Scale ≤ 2\n* Life expectancy is more than 6 months\n* WBC ≥ 3500\u002Fμl, granulocyte ≥ 1500\u002Fμl\n* Platelet count ≥60,000\u002Fμl\n* Calculated or measured creatinine clearance ≥ 30cc\u002Fmin. Calculated or measured creatinine clearance can be ≥ 40cc\u002Fmin given stability of creatinine levels over the past three weeks (at least 1 test per week).\n* AST and ALT ≤ 2.5 X upper limit of normal (ULN)\n* INR \\\u003C 1.4 for patients not on Warfarin\n* Subjects are willing and able to sign an informed consent form\n* Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after brachytherapy.\n* Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.\n\nExclusion Criteria:\n\n* Concomitant chemotherapy or immunotherapy within the past 4 weeks\n* Prior radiation therapy to the pancreas\n* CA 19-9 \\> 1000 Units\u002Fml\n* Fit for surgical exploration unless the patient refuses surgery\n* Known hypersensitivity to any of the components of the treatment.\n* Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids.\n* Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.\n* Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy (not including cholangitis) or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints.\n* Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n* Patient requires treatment not specified in this protocol which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT.\n* Patients do not agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.\n* Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.\n* High probability of protocol non-compliance (in opinion of investigator).\n* Breastfeeding women or women of childbearing potential unwilling or unable to use an acceptable contraceptive method to prevent pregnancy for 3 months after RT.","ALL","18 Years","120 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer",[27,28,29],"Pancreatic Cancer","Unresectable Pancreatic Cancer","Pancreatic Adenocarcinoma",[31,28,29,32,33],"pancreatic cancer","Alpha radiation","Pancreas Cancer","RECRUITING","2026-06-15",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":38},"2026-05-06",{"date":42,"type":21},"2028-01",{"name":44,"class":45},"Alpha Tau Medical LTD.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":25,"conditions":56,"keywords":58,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100489793","alpha-radiation-emitters-device-for-the-treatment-of-advanced-pancreatic-cancer-feasibility-and-safety-100489793","NCT05657743","Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)","A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer","Inclusion Criteria\n\n* Histologically and\u002For cytologically proven locally advanced or metastatic pancreatic adenocarcinoma\n* Patients must have i) received at least one line of chemotherapy OR ii) are medically unfit for further chemotherapy, AND iii) the tumor is still not deemed as resectable with radical surgery or the patient does not wish to go through surgery\n* Target lesion is technically amenable for at least 50% coverage by the Alpha DaRT seeds as determined by the treating physician\n* Interstitial radiation indication validated by a multidisciplinary team\n* Measurable lesion per RECIST (version 1.1) criteria\n* Lesion size ≤ 5 cm in the longest diameter\n* Age ≥18 years old\n* ECOG Performance Status Scale ≤ 2\n* Life expectancy is more than 6 months\n* WBC ≥ 3500\u002Fµl, granulocyte ≥ 1500\u002Fµl\n* Platelet count ≥60,000\u002Fµl\n* Calculated or measured creatinine clearance ≥ 60cc\u002Fmin. Calculated or measured creatinine clearance can be≥ 40cc\u002Fmin given stability of creatinine levels over the past three weeks (at least 1 test per week).\n* AST and ALT ≤ 2.5 X upper limit of normal (ULN)\n* INR \\\u003C 1.4 for patients not on Warfarin\n* Subjects are willing and able to sign an informed consent form\n* Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after brachytherapy.\n* Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.\n\nExclusion Criteria:\n\n* Concomitant chemotherapy or immunotherapy within the past 4 weeks\n* Brain metastases\n* Borderline unresectable pancreatic cancer, and\u002For cases fit for surgical exploration unless patient refuses surgery\n* Known hypersensitivity to any of the components of the treatment.\n* Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids.\n* Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months.\n* Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial or interfere with the study endpoints.\n* Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n* Patient requires treatment not specified in this protocol which may conflict with the endpoints of this study including evaluation of response or toxicity of DaRT.\n* Patients do not agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.\n* Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT.\n* High probability of protocol non-compliance (in opinion of investigator).\n* Breastfeeding women or women of childbearing potential unwilling or unable to use an acceptable contraceptive method to prevent pregnancy for 3 months after RT.",{"count":20,"type":21},[24],[27,28,57,29],"Metastatic Pancreatic Cancer",[31,28,57,29,59,32,60],"Pancreas Neoplasm","Pancreas Metastases",{"date":37,"type":38},{"date":63,"type":38},"2023-08-16",{"date":65,"type":21},"2027-11",{"name":44,"class":45},2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100537486","phase-1-safety-and-efficacy-of-nrt6008-in-patients-with-unresectable-locally-advanced-pancreatic-cancer-lapc-and-advanced-pancreatic-cancer-with-lymph-node-metastases-100537486","NCT06278454","Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases","A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of NRT6008 Injection in Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases","Inclusion Criteria:\n\n1. Aged ≥18 years and ≤80 years, able to comprehend and sign an informed consent form;\n2. Diagnosed with pancreatic adenocarcinoma confirmed histologically or cytologically;\n3. Evaluated as unresectable LAPC or metastatic pancreatic cancer with lymph node metastasis only, as determined by the investigator; or having contraindications to surgery, or refusing surgical resection;\n4. ECOG performance status score ≤1;\n5. Expected survival ≥3 months;\n6. According to RECIST v1.1 criteria, there is only one measurable lesion in the pancreas confirmed by imaging, and the lesion has the shortest axis diameter ≥2.0 cm, the longest axis diameter ≤6.0 cm (based on baseline imaging);\n7. Adequate normal organ and marrow function as defined below: (1) Renal function: serum creatinine ≤1.5×ULN, or creatinine clearance ≥60 mL\u002Fmin (calculated by the Cockcroft-Gault formula); (2) Liver function: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3×ULN; serum total bilirubin ≤1.5×ULN; (3) Bone marrow function \\[\\[no blood transfusion or granulocyte colony-stimulating factor (G-CSF), human thrombopoietin (TPO), or TPO receptor agonist treatment within 14 days prior to signing informed consent\\]: neutrophils ≥1.5×10\\^9\u002FL, hemoglobin ≥90 g\u002FL, platelets ≥100×10\\^9\u002FL; (4) Coagulation function: International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN;\n8. Female and male participants of reproductive age must voluntarily agree to practice strict and effective contraception after signing the informed consent form, during the study period, and within 12 months after administration of the investigational drug. Males are prohibited from donating sperm during this period. Female participants of reproductive age must have a negative pregnancy test result during the screening period and within 24 hours before administration of the investigational drug.\n\nExclusion Criteria:\n\n1. Allergic to the investigational drug NRT6008 injection itself or any of its components;\n2. Contraindications to any of the three optional systemic chemotherapy regimens in this study judged by investigators;\n3. Previous anti-tumor treatments for pancreatic cancer, including but not limited to chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. Except for discontinuation of traditional chinese medicine or herbal medicine for at least 7 days prior to the screening period;\n4. Contraindications to anesthesia;\n5. History of any other malignant tumors within 5 years before receiving investigational drug treatment, except for cases of cured non-melanoma skin cancer, cervical carcinoma in situ, or basal cell carcinoma of the skin, Stage I Grade 1 endometrial carcinoma, or thyroid cancer;\n6. Presence or suspected presence of distant metastases according to imaging;\n7. Pregnant or lactating females;\n8. Participants assessed by the investigators to be at high risk or had difficulty in operation for EUS-FNI procedures;\n9. Evidence of radiographic invasion into stomach, duodenum or peritoneum;\n10. Participants with chronic diseases that are actively treated but not well controlled, such as primary hypertension, diabetes, etc.;\n11. Within 6 months prior to the the first administration of chemotherapy, occurrence of acute pancreatitis, severe gastrointestinal bleeding, severe cardiovascular diseases (including but not limited to stroke, unstable angina), or occurrence of acute infections requiring systemic treatment within 2 weeks before the screening period;\n12. Participated in other interventional clinical trials within 1 month prior to the first administration of chemotherapy;\n13. Positive for human immunodeficiency virus (HIV) antibodies;\n14. Positive for hepatitis B virus (HBV) surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb), HBV DNA testing required, participants with HBV-DNA levels below the lower limit of the reference range or \\\u003C 500 IU\u002FmL will be eligible for inclusion in this study (use of antiviral drugs during the study period is required);\n15. Positive for hepatitis C virus (HCV) antibodies, HCV RNA testing required, participants with negative HCV RNA results will be eligible for inclusion in this study;\n16. Participants with syphilis infection or active tuberculosis;\n17. Other reasons deemed unsuitable for participation in this trial by the investigators.","80 Years",{"count":77,"type":21},58,[79],"PHASE1","This is a single arm, open label, multi-center phase I study, including phase Ia dose escalation and phase Ib dose expansion. Safety review committee (SRC) will be formed to monitor safety and efficacy data through the study. And the independent review committee (IRC) will be formed to monitor efficacy data through the study.",[28,82,83],"Advanced Pancreatic Cancer","Lymph Node Metastases",[85,86,87,88],"Yttrium-90","Endoscopic ultrasound-guided fine-needle injection","Locally Advanced Pancreatic Carcinoma","Advanced Pancreatic Cancer with Lymph Node Metastases","2026-06-08",{"date":91,"type":38},"2026-06-10",{"date":93,"type":38},"2024-01-09",{"date":95,"type":21},"2028-06",{"name":97,"class":45},"Chengdu New Radiomedicine Technology Co. LTD.",6,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":67},"100423102","phase-1-nano-smart-nanoparticles-with-mr-guided-sbrt-in-centrally-located-lung-tumors-and-pancreatic-cancer-100423102","NCT04789486","Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer","Nano-SMART: An Adaptive Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\nPatients should have clinical, radiographical, cytological, or histological confirmation of NSCLC or lung or nodal metastases from another primary cancer defined as within or touching the zone of the proximal bronchial tree, defined as a volume 2 cm in all directions around the trachea and proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus right and left lower lobe bronchi). Tumors that are immediately adjacent (\\\u003C1 cm) to mediastinal or pericardial pleura or other radiation-sensitive organs such as the esophagus and brachial plexus also are considered central tumors and are eligible for this protocol.\n\nOR Histologically or cytologically confirmed pancreatic ductal adenocarcinoma of the pancreatic head, body or tail.\n\n* Participants must have measurable disease, defined as a lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. See Section 11 for the evaluation of measurable disease.\n\nEligible NSCLC patients must have no evidence of nodal involvement (N0), and disease has to be determined unresectable by a thoracic oncologist or the patient is medically inoperable.\n\n* Locally advanced, unresectable pancreatic cancer as determined by a pancreaticobiliary surgeon as part of a multidisciplinary discussion at the investigative site, including multi-phasic CT demonstrating tumor abutment of the SMA or celiac axis, SMV or PV involvement which is not resectable without vascular reconstruction.\n* Completion of at least 3 months of standard induction chemotherapy for LAPC, which should consist of either FOLFIRINOX, gemcitabine and nab-paclitaxel, or another standard combination of induction chemotherapy agent, with a washout period no longer than 10 weeks prior to first dose of study drug.\n* No evidence of distant metastasis.\n* Pancreatic or central NSCLC size ≤ 5cm.\n* Age 18 years or older.\n* ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).\n* Ability to understand and follow the breathing instructions involved in the respiratory gating procedure.\n* Participants must have normal organ and marrow function as defined below:\n\n  * absolute neutrophil count ≥1,500\u002FmcL\n  * platelets ≥100,000\u002FmcL\n  * total bilirubin within normal institutional limits\n  * AST(SGOT)\u002FALT(SGPT) ≤2.5 × institutional upper limit of normal\n  * creatinine within normal institutional limits OR\n* Creatinine clearance ≥60 mL\u002Fmin\u002F1.73 m2 for participants with creatinine levels above institutional normal.\n* The effects of AGuIX on the developing human fetus are unknown. For this reason, as well as the known teratogenic effects of radiation, women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who have had prior radiation therapy to the chest or abdomen that would overlap with the current treatment field.\n* Participants who are receiving any other investigational agents.\n* Participants with known metastatic disease.\n* History of allergic reactions attributed to gadolinium-based IV contrast.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because AGuIX is contrast agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AGuIX, breastfeeding should be discontinued if the mother is treated with AGuIX.\n* Severe claustrophobia or anxiety.\n* Known HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AGuIX. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.\n* Active duodenal or gastric ulcer disease or evidence of tumor invasion of the bowel or stomach based on endoscopy.\n* Presence of a duodenal stent.\n* Unable to undergo magnetic resonance imaging (MRI) due to any of the following:\n\n  1. Presence of MRI-incompatible metal material or devices in the human body\n  2. MRI-incompatible Pacemaker or defibrillator\n  3. Insulin pump\n  4. Aneurysm clip\n  5. Artificial heart valve\n  6. Cochlear implant\n  7. Shrapnel or gunshot injury\n  8. Cataract surgery with implant unsafe for MRI",{"count":107,"type":21},100,[79,109],"PHASE2","This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation therapy (SBRT) in the treatment of pancreatic cancer and lung tumors.",[112,113,28,114],"Non-small Cell Lung Cancer","Advanced Pancreatic Adenocarcinoma","Ductal Adenocarcinoma of the Pancreas",[112,113,28,114],"2026-05-12",{"date":118,"type":38},"2026-05-14",{"date":120,"type":38},"2021-05-27",{"date":122,"type":21},"2030-04-10",{"name":124,"class":125},"Dana-Farber Cancer Institute","OTHER",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":46},"100608215","early-phase-1-a-single-arm-investigator-initiated-tria-iit-evaluating-the-safety-and-preliminary-efficacy-of-autologous-drug-loaded-neutrophils-neumed-in-patients-with-unresectable-pancreatic-cancer-100608215","NCT07198659","A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer","A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer（NeuMed-uPC）","NeuMed-uPC","Inclusion Criteria:\n\n* 18-70 years\n* Obtain an informed consent form voluntarily signed by the patient themselves\n* patients with Unresectable Pancreatic Cancer confirmed by Histopathology\n* Patients who either: 1) have received standard first-line treatments, proven ineffective or causing intolerable adverse effects; or 2) have not received the standard first-line treatments and voluntarily opt for Autologous Drug-Loaded Neutrophils (NeuMed)-based therapy\n* EOCG score ≤ 2 and expected survival time ≥ 3 months\n* Liver, kidney and bone marrow functions are basically normal\n\nExclusion Criteria:\n\n* Patients who required anti coagulant therapy\n* Patients with active infectious diseases or a history of bone marrow or organ transplantation\n* Patients with autoimmune diseases or autoinflammatory diseases\n* Patients with a history of severe cardiovascular or cerebrovascular diseases or interstitial lung disease or non-infectious pneumonia\n* Patients who have received live vaccines within 30 days prior to enrollment\n* Patients with no response to bone marrow mobilization\n* Other patients deemed unsuitable for enrollment by the investigator","70 Years",{"count":136,"type":21},3,[138],"EARLY_PHASE1","The goal of this clinical trial is to learn if Autologous Drug-Loaded Neutrophils (NeuMed) can treat patients with Unresectable Pancreatic Cancer. The drug carried by the Autologous Neutrophils is Monomethyl Auristatin E. The main questions it aims to answer are: First, to verify the safety of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer. Second, to assess the anti-tumor efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer.",[28],[142,28,143],"Autologous Drug-Loaded Neutrophils (NeuMed)","Monomethyl Auristatin E (MMAE)","2025-09-26",{"date":146,"type":38},"2025-09-30",{"date":148,"type":38},"2025-07-14",{"date":150,"type":21},"2027-07-14",{"name":152,"class":125},"The First Affiliated Hospital of Air Force Medicial University",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":161,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":46},"100526527","phase-2-tripegfilgrastim-trial-to-reduce-the-risk-of-severe-neutropenia-in-patients-with-unresectable-pancreaticobiliary-cancers-100526527","NCT06135896","Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers","An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers","Dulastin","Inclusion Criteria:\n\n* Patients aged at least 19 years old, diagnosed with unresectable pancreaticobiliary cancer, and scheduled to receive chemotherapy using nal-IRI\u002F5-FU\u002FLV combination chemotherapy\n\nExclusion Criteria:\n\n* Patients who refuse to sign the consent form Patients who have previously experienced severe neutropenia during chemotherapy","19 Years",{"count":163,"type":21},98,[109],"* Clinical trial phase: Phase 2\n* Intervention model: Control group\n* Group allocation: Randomized controlled trial\n* Research perspective: Prospective study\n* Participating centers: Multicenter study\n* Definition of the intervention period: Based on the RECIST 1.1 guidelines, patients will receive treatment until dropout due to disease progression or unacceptable toxicity related to the trial drug. Patients will be followed up with to assess survival every 2 months until either death or the end of the trial, whichever is first.\n* The intervention period is from the date of IRB approval to December 31st, 2025\n* The follow-up duration is one year, and the statistical analysis duration is six months\n* The total research period is from the date of IRB approval to June 30th, 2026",[28,167,168],"Unresectable Bile Duct Carcinoma","Unresectable Biliary Tract Carcinoma",[28,167,168],"2025-06-15",{"date":172,"type":38},"2025-06-18",{"date":174,"type":38},"2024-01-16",{"date":176,"type":21},"2026-06-30",{"name":178,"class":179},"National Cancer Center, Korea","OTHER_GOV",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100523701","phase-4-efficacy-of-pert-for-pei-in-unresectable-pancreatic-cancer-100523701","NCT06099119","Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.","Open Label Randomized, Multicentre, Controlled Trial of Pancreatic Enzyme Replacement Therapy (PERT) for Pancreatic Exocrine Insufficiency (PEI) in Patients With Unresectable Pancreatic Cancer. The PERTseverance Trial.","PERTseverance","Inclusion Criteria:\n\n1. Pathologically confirmed unresectable, locally advanced or metastatic, pancreatic cancer.\n2. Tumour located in the head of the pancreas.\n3. Dilated main pancreatic duct confirmed by imaging methods (CT scan, MRI and\u002For EUS).\n4. Significant weight loss (≥5% of the usual body weight) at screening.\n5. Life expectancy of at least six months at screening.\n6. Signed informed consent to the study.\n\nExclusion Criteria:\n\n1. Hypersensitivity to pancreatin of porcine origin or to any of the excipients.\n2. Patients on neoadjuvant therapy, or in whom neoadjuvant therapy is planned.\n3. Patients already on PERT.\n4. Prior history of upper gastrointestinal or pancreatic surgery.\n5. Short life expectancy (shorter than 6 months).\n6. Patients on second line or beyond chemotherapy (those who failed with first line chemotherapy therapy).\n7. Patients in whom a pancreatic stent has been placed.\n8. Unsolved gastric outlet obstruction.\n9. Unwillingness to participate in the study.\n10. Inability to comply with the study visits and study protocol, whatever the reason.",{"count":107,"type":21},[190],"PHASE4","\\- This will a be an open label, multicentre, randomized, controlled study in patients with unresectable pancreatic cancer, locally advanced or metastatic, with significant weight loss, and the tumour located in the head of the pancreas associated with dilated main pancreatic duct. Pancreatic Exocrine Replacement Therapy (PERT) in these patients will be given on top of other required therapies (best standard of care, BSC), including oncologic therapies, diabetes mellitus therapies and acid suppressants and nutritional support as appropriate. The duration of the study will be up to six months.\n\nConsecutive patients meeting inclusion criteria and none of the exclusion criteria will be evaluated for the study. Those patients signing the informed consent for study participation will be randomized to one of the following two arms:\n\n* The experimental arm will receive the best standard of care (BSC) and PERT (capsules containing pancreatin 35,000 Ph.U.) at a fixed dose of 3 capsules with main meals (breakfast, lunch and dinner) and 2 capsules with snacks over 6 months.\n* The control arm will receive the BSC over 3 months, followed by a further 3-month open uncontrolled phase of BSC + PERT at the dose mentioned above.\n\nAll patients will receive in addition a proton pump inhibitor (PPI) bid (any PPI at standard dose is acceptable -omeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, rabeprazole 20 mg, esomeprazole 40 mg) while on PERT, 20-30 minutes before breakfast and dinner.\n\nTo make the two arms comparable, patients will be stratified in two groups (locally advanced and metastatic pancreatic cancer) for randomization using computer generated random numbers.",[28],"2025-06-03",{"date":195,"type":38},"2025-06-06",{"date":197,"type":38},"2024-02-20",{"date":199,"type":21},"2026-12",{"name":201,"class":125},"Hospital Clinico Universitario de Santiago",4]